EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications

Tomoko Akaike iD, Manisha Thakuria iD, Ann W Silk iD, Daniel S Hippe iD, Song Youn Park iD, Naomi A So, Nolan J Maloney, Lindsay Gunnell, Alec Eschholz, Emily Y Kim iD, Sumi Sinha iD, Evan Thomas Hall iD und 12 weitere

Journal of Clinical Oncology · 10.09.2024 · 42 (26) · 3151-3161

DOI: 10.1200/jco.23.02054 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.09.2024. Verfasst von Tomoko Akaike und 23 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington, Seattle, WA. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Circulating Tumor DNA, Neoplasm Recurrence, Local, Skin Neoplasms. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Merkel cell carcinoma (MCC) is an aggressive skin cancer with a 40% recurrence rate, lacking effective prognostic biomarkers and surveillance methods. This prospective, multicenter, observational study aimed to evaluate circulating tumor DNA (ctDNA) as a biomarker for detecting MCC recurrence. METHODS Plasma samples, clinical data, and imaging results were collected from 319 patients. A tumor-informed ctDNA assay was used for analysis. Patients were divided into discovery (167 patients) and validation (152 patients) cohorts. Diagnostic performance, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), was assessed. RESULTS ctDNA showed high sensitivity, 95% (discovery; 95% CI, 87 to 99) and 94% (validation; 95% CI, 85 to 98), for detecting disease at enrollment, with corresponding specificities of 90% (95% CI, 82 to 95) and 86% (95% CI, 77 to 93). A positive ctDNA during surveillance indicated increased recurrence risk, with hazard ratios (HRs) of 6.8 (discovery; 95% CI, 2.9 to 16) and 20 (validation; 95% CI, 8.3 to 50). The PPV for clinical recurrence at 1 year after a positive ctDNA test was 69% (discovery; 95% CI, 32 to 91) and 94% (validation; 95% CI, 71 to 100), respectively. The NPV at 135 days after a negative ctDNA test was 94% (discovery; 95% CI, 90 to 97) and 93% (validation; 95% CI, 89 to 97), respectively. Patients positive for ctDNA within 4 months after treatment had higher rates of recurrence, with 1-year rates of 74% versus 21% (adjusted HR, 7.4 [95% CI, 2.7 to 20]). CONCLUSION ctDNA testing exhibited high prognostic accuracy in detecting MCC recurrence, suggesting its potential to reduce frequent surveillance imaging. ctDNA also identifies high-risk patients who need more frequent imaging and may be best suited for adjuvant therapy trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellCirculating Tumor DNANeoplasm Recurrence, LocalSkin NeoplasmsDisease ProgressionNeoplasm, ResidualHumansMaleFemaleAgedProspective StudiesMiddle AgedPrognosisAged, 80 and overBiomarkers, TumorAdult

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • University of Washington, Seattle, WA.
  • Brigham and Women's Hospital, Boston, MA.
  • Dana-Farber Cancer Institute, Boston, MA.
  • Harvard Medical School, Boston, MA.
  • Fred Hutchinson Cancer Center, Seattle, WA.
  • Stanford University School of Medicine, Palo Alto, CA.

ORCID-Profile: Tomoko Akaike, Manisha Thakuria, Ann W Silk, Daniel S Hippe, Song Youn Park, Emily Y Kim, Sumi Sinha, Evan Thomas Hall, Shailender Bhatia, Alexey Aleshin, Jacob S Choi, Kenneth Y Tsai, Sue S Yom, Jaehyuk Choi, Sunandana Chandra, Paul Nghiem, Lisa C Zaba

Förderung

  • NCI NIH HHS

Zitieren

APA

Akaike, T., Thakuria, M., Silk, A. W., Hippe, D. S., Park, S. Y., So, N. A., Maloney, N. J., Gunnell, L., Eschholz, A., Kim, E. Y., Sinha, S., Hall, E. T., Bhatia, S., Reddy, S., Rodriguez, A. A., Aleshin, A., Choi, J. S., Tsai, K. Y., Yom, S. S., …, & Zaba, L. C. (2024). Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications. Journal of Clinical Oncology, 42(26), 3151-3161. https://doi.org/10.1200/jco.23.02054

Vancouver

Akaike T, Thakuria M, Silk AW, Hippe DS, Park SY, So NA, et al. Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications. Journal of Clinical Oncology. 2024;42(26):3151-3161. doi:10.1200/jco.23.02054

BibTeX
@article{Akaike2024,
  author = {Akaike, Tomoko and Thakuria, Manisha and Silk, Ann W and Hippe, Daniel S and Park, Song Youn and So, Naomi A and Maloney, Nolan J and Gunnell, Lindsay and Eschholz, Alec and Kim, Emily Y and Sinha, Sumi and Hall, Evan Thomas and Bhatia, Shailender and Reddy, Sunil and Rodriguez, Angel Augusto and Aleshin, Alexey and Choi, Jacob S and Tsai, Kenneth Y and Yom, Sue S and Yu, Siegrid S and Choi, Jaehyuk and Chandra, Sunandana and Nghiem, Paul and Zaba, Lisa C},
  title = {Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {26},
  pages = {3151--3161},
  doi = {10.1200/jco.23.02054}
}
Kostenlos starten →